CTLA-4 and PD-1 are up-regulated when T cells become activated, which in the case of PD-1 has also been linked to neo-antigen specificity [48], and since the introduction of ICI, we know that selectively inhibiting these immune checkpoints can result in unprecedented anti-tumor activity. This evidence concerns the gene CTLA4 and neoplasm.